Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUE NASDAQ:CRBU NASDAQ:GNFT NASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACRBUCaribou Biosciences$2.28-3.8%$1.41$0.66▼$3.00$220.42M2.482.24 million shs1.75 million shsGNFTGENFIT$3.88-2.6%$4.02$2.55▼$6.42$199.06M1.083,966 shs758 shsRAPTRapt Therapeutics$13.31+5.2%$8.88$5.67▼$27.84$209.18M-0.09130,058 shs66,312 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%0.00%0.00%+19.47%-78.39%CRBUCaribou Biosciences-3.80%+11.22%+60.56%+194.57%+0.88%GNFTGENFIT-4.56%+1.57%+2.13%+6.46%-8.39%RAPTRapt Therapeutics+5.22%+13.96%+39.23%+89.36%-47.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio1.7457 of 5 stars3.10.00.00.00.61.71.3CRBUCaribou Biosciences2.6344 of 5 stars3.53.00.00.02.21.70.6GNFTGENFIT2.4947 of 5 stars3.55.00.00.02.70.00.0RAPTRapt Therapeutics4.365 of 5 stars3.24.00.04.23.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCRBUCaribou Biosciences 3.00Buy$8.50272.81% UpsideGNFTGENFIT 3.00Buy$13.00235.48% UpsideRAPTRapt Therapeutics 2.43Hold$21.6762.78% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, RAPT, GNFT, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025RAPTRapt TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$31.007/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.005/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CRBUCaribou Biosciences$9.99M21.23N/AN/A$2.79 per share0.82GNFTGENFIT$76.77M2.52$0.07 per share56.92$1.50 per share2.58RAPTRapt Therapeutics$1.53M143.89N/AN/A$11.51 per share1.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/ARAPTRapt Therapeutics-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)Latest BLUE, RAPT, GNFT, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RAPTRapt Therapeutics-$0.68N/AN/AN/AN/AN/A8/12/2025Q1 2025BLUEbluebird bio-$1.91N/AN/AN/A$45.60 millionN/A8/5/2025Q2 2025CRBUCaribou Biosciences-$0.40N/AN/AN/AN/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CRBUCaribou BiosciencesN/A7.637.63GNFTGENFIT0.081.231.23RAPTRapt TherapeuticsN/A21.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CRBUCaribou Biosciences77.51%GNFTGENFIT2.24%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CRBUCaribou Biosciences8.28%GNFTGENFIT4.20%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRBUCaribou Biosciences10093.00 million85.30 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableBLUE, RAPT, GNFT, and CRBU HeadlinesRecent News About These CompaniesRapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street ZenJuly 26 at 3:26 AM | marketbeat.comQ2 Earnings Forecast for RAPT Issued By Lifesci CapitalJuly 25 at 6:12 AM | marketbeat.comLifesci Capital Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Strong-BuyJuly 25 at 3:59 AM | americanbankingnews.comLifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform RecommendationJuly 23 at 4:42 PM | msn.comRapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci CapitalJuly 23 at 8:10 AM | marketbeat.comRapt Therapeutics initiated with an Outperform at LifeSci CapitalJuly 23 at 6:36 AM | msn.comRapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 23 at 3:32 AM | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from AnalystsJuly 23 at 3:32 AM | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15, 2025 | msn.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15, 2025 | zacks.comAegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the BoardJuly 15, 2025 | tmcnet.comBest Momentum Stocks to Buy for July 15thJuly 15, 2025 | zacks.comDoes Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?July 15, 2025 | zacks.comNew Strong Buy Stocks for July 15thJuly 15, 2025 | zacks.comHC Wainwright Analysts Decrease Earnings Estimates for RAPTJuly 14, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) StockJuly 10, 2025 | marketbeat.comRAPT Therapeutics Inc.July 5, 2025 | barrons.comRAPT Therapeutics Inc Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMRapt Therapeutics (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsJune 28, 2025 | marketbeat.comRAPT Therapeutics expands board with two new directorsJune 25, 2025 | investing.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors - NasdaqJune 25, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonPepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?5 High-Yielding ETFs to Buy and Hold ForeverBy Ryan Hasson | June 30, 2025View 5 High-Yielding ETFs to Buy and Hold ForeverBLUE, RAPT, GNFT, and CRBU Company Descriptionsbluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Caribou Biosciences NASDAQ:CRBU$2.28 -0.09 (-3.80%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.34 +0.06 (+2.63%) As of 07/25/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.GENFIT NASDAQ:GNFT$3.88 -0.11 (-2.64%) Closing price 07/25/2025 03:56 PM EasternExtended Trading$3.88 0.00 (0.00%) As of 07/25/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Rapt Therapeutics NASDAQ:RAPT$13.31 +0.66 (+5.22%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$12.94 -0.37 (-2.78%) As of 07/25/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
